Date published: 2026-4-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

Gimeracil (CAS 103766-25-2)

5.0(1)
Write a reviewAsk a question

See product citations (2)

Alternate Names:
5-Chloro-4-hydroxy-2(1H)-pyridinone; 5-Chloro-2,4-dihydroxypyridine; 5-Chloro-4-hydroxy-2-pyridone; Gimestat; CDHP
Application:
Gimeracil is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD)
CAS Number:
103766-25-2
Purity:
≥99%
Molecular Weight:
145.54
Molecular Formula:
C5H4ClNO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Gimeracil is an antitumor agent and a potent inhibitor of dihydropyrimidine dehydrogenase (DPD).


Gimeracil (CAS 103766-25-2) References

Shirasaka, T., et al.: Cancer Res., 56, 2602 (1996), Patt, Y., et al.: J. Clin. Oncol., 22, 271 (2004), Shirao, K., et al.: Cancer, 100, 2355 (2004), Kelly, H., et al.: J. Clin. Oncol., 23, 4553(2005),

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Gimeracil, 25 mg

sc-207714
25 mg
$166.00

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. The compound, sc-207714, is provided as a white to light yellow crystalline powder. If you have any further questions or concerns, please feel free to contact our Technical Service department by calling 800-457-3801 option 2, emailing scbt@scbt.com, or using the Live Chat function on our website.
Answered by: Tech Service 8
Date published: 2017-02-10

What is the solubility of this compound?

Asked by: two2igm05
Thank you for your question. The solubility (at 25ºC) for sc-207714 is as follows: DMSO (29 mg/mL), Water (<1 mg/mL), and Ethanol (<1 mg/mL). The designation of "<1 mg/mL" means that it is slightly soluble or insoluble. If you have any further questions, please contact our Technical Service department by calling 800-457-3801 option 2, emailing scbt@scbt.com, or using the Live Chat function on our website.
Answered by: Tech Service 8
Date published: 2016-12-23
  • y_2026, m_4, d_9, h_7CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_2
  • loc_en_US, sid_207714, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getContent, 94ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Kawahara et alKawahara et al. (PubMed ID 25109221) used the dihydropyrimidine dehydrogenase inhibitor gimeracil as a part of S-1, an oral fluoropyrimidine derivative, for the treatment of non-small cell lung cancer. -SCBT Publication Review
Date published: 2015-04-24
  • y_2026, m_4, d_9, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_207714, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getReviews, 16ms
  • REVIEWS, PRODUCT
Gimeracil is rated 5.0 out of 5 by 1.
  • y_2026, m_4, d_9, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.43
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_207714, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getAggregateRating, 139ms
  • REVIEWS, PRODUCT